Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Teva
Harvard Business School
Merck
Healthtrust
Chinese Patent Office
Dow
Argus Health
Farmers Insurance

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,759,328

« Back to Dashboard

Which drugs does patent 7,759,328 protect, and when does it expire?

Patent 7,759,328 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-seven countries.
Summary for Patent: 7,759,328
Title:Composition for inhalation
Abstract:The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
Inventor(s): Govind; Nayna (Leicestershire, GB), Marlow; Maria (Leicestershire, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/502,685
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,759,328
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 7,759,328

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,759,328

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0200312Feb 01, 2002
Sweden0200312Feb 1, 2002
PCT Information
PCT FiledJanuary 29, 2003PCT Application Number:PCT/SE03/00156
PCT Publication Date:August 07, 2003PCT Publication Number: WO03/063842

Non-Orange Book US Patents Family Members for Patent 7,759,328

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,143,239 Composition for inhalation ➤ Sign Up
8,575,137 Composition for inhalation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
Cerilliant
Julphar
Teva
Queensland Health
UBS
Cipla
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.